{"id":2155,"date":"2019-10-02T12:21:52","date_gmt":"2019-10-02T10:21:52","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2155"},"modified":"2024-11-05T15:48:05","modified_gmt":"2024-11-05T14:48:05","slug":"neurologic-diseases-and-neurogenetics-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/neuroscience-area\/neuroscience-program\/neurologic-diseases-and-neurogenetics-2\/","title":{"rendered":"Neurologic Diseases and Neurogenetics"},"content":{"rendered":"\n

\n\t\tNeurologic diseases and neurogenetics\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls Foundation).he group works in the development of new diagnostic and prognostic biomarkers and cl\u00ednical, epidemiological studies in neurologial diseases.<\/p>\n

619<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"pyramidal_hippocampal_neuron_40x\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tBiomarkers in neurological disease: ALS, MS, Alzheimer’s Disease…
\nNew therapeutic strategies in Neurological Diseases
\nEpidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
\nLexical access disorders in speech production
\nProthrombotic mechanisms in patients with Stroke
\nNeurophysiological markers in postanoxic patients
\nNeuronal networks and Epilepsy
\nPersonalized and Precision Medicine in neurological disease
\nPrognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia…\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t